Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (symbol: VVOS) is a leading medical technology company dedicated to providing innovative solutions for patients suffering from sleep disordered breathing (SDB), particularly mild-to-moderate obstructive sleep apnea (OSA). The company specializes in the development and commercialization of proprietary treatment protocols and customized oral appliances, known collectively as the Vivos System. This non-surgical, non-invasive, and non-pharmaceutical system is designed to address craniofacial and anatomical anomalies associated with OSA, offering a cost-effective alternative to traditional treatments.
The Vivos System combines the expertise of specially trained dentists and medical professionals to deliver comprehensive care. Through its Vivos Integrated Healthcare Network, the company enables healthcare providers, including general dentists, medical doctors, myofunctional therapists, and chiropractors, to offer targeted therapies for SDB. Additionally, Vivos licenses its intellectual property to third-party manufacturers to fabricate these advanced appliance devices, expanding its reach and impact.
Recent developments at Vivos Therapeutics highlight the company's commitment to improving patient outcomes. The favorable update to United Healthcare's medical policy now endorses oral appliance therapies, potentially increasing the adoption of Vivos devices. Furthermore, the recall of numerous CPAP devices by ResMed and Philips Respironics presents a significant revenue opportunity for Vivos.
The company has also achieved a significant milestone with the introduction of the first Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults. This breakthrough enhances the accessibility of effective OSA treatment to a broader patient population.
Vivos Therapeutics continues to position itself as a pioneer in the medical technology space, driven by its mission to improve the quality of life for patients with sleep-disordered breathing. Stay informed about Vivos Therapeutics' latest news and developments to understand the dynamic landscape of this innovative company.
Vivos Therapeutics (NASDAQ: VVOS) announced a significant surge in its Home Sleep Apnea Tests (HST) for the three months ending December 31, 2021.
Key metrics include an 18x increase in total HSTs, a 5.7x rise in the number of dentists administering these tests, and a 3x increase in average tests per dentist.
This performance led to a renegotiated agreement with SleepImage, reducing costs and establishing a recurring revenue model. With over one billion people suffering from sleep apnea, Vivos aims to leverage its new arrangement to improve patient access to treatments.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that its mmRNA device is now covered by Medicare, marking a significant milestone for the treatment of obstructive sleep apnea (OSA) and snoring. This acceptance by the Centers for Medicare & Medicaid Services (CMS) allows millions of Medicare beneficiaries to access this innovative non-surgical solution. The mmRNA device is designed to provide effective therapy for mild to moderate OSA, and enhances commercial insurance coverage prospects. Approximately 54 million Americans suffer from sleep apnea, with many undiagnosed.
Vivos Therapeutics (NASDAQ: VVOS) has officially registered its products with Health Canada, enabling local dentists to provide comprehensive solutions for obstructive sleep apnea (OSA). The initiative aims to enhance patient outcomes through clinical screening, diagnosis, and treatment with Vivos’ oral appliances. Approximately 25,000 Canadian dentists are expected to utilize Vivos products, which have been effective for over 22,000 patients worldwide. The company plans to expand its manufacturing capacity in Canada to support this initiative, responding to strong demand for its innovative therapies.
Vivos Therapeutics, Inc. will present at the Benzinga Global Small Cap Conference on December 9, 2021, at 1:55 PM EST. The company's executives, including Chairman Kirk Huntsman and CFO Brad Amman, will discuss its innovative treatment for mild to moderate obstructive sleep apnea (OSA) using the Vivos System. This system is a non-surgical solution proven effective for over 22,000 patients worldwide. Interested investors can register for a free spectator pass and view the presentation online.
Vivos Therapeutics reported a 38% increase in Q3 revenue to $4.5 million, with a total of $12.5 million for the first nine months of 2021. Appliance sales surged by 33% in Q3, totaling 2,996 units sold. The company received FDA 510(k) clearance for its mmRNA device, enhancing reimbursement prospects. Despite a slight decrease in dentist enrollments due to COVID-19, strategic partnerships and new training facilities position Vivos for future growth. Gross margin decreased to 70% from 78% year-over-year, while cash reserves stand at $28.5 million.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q4 Virtual Investor Summit on November 17, 2021, at 11:45 am EST. The presentation features CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Investors can register for the event through the provided link and view a replay on Vivos’ website post-presentation. Vivos specializes in treatments for obstructive sleep apnea (OSA), promoting their innovative Vivos System as a non-surgical, cost-effective solution. The company has treated over 19,000 patients with their oral appliances.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its third-quarter financial results on November 15, 2021, after market close. The company will conduct a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outline its growth strategy. Known for developing innovative treatments for obstructive sleep apnea, Vivos utilizes customized oral appliances in its Vivos System. The company has effectively treated over 19,000 patients globally, emphasizing its commitment to non-invasive solutions for OSA.
Vivos Therapeutics (NASDAQ: VVOS) will present at the Benzinga Global Small Cap Conference at 12:15 PM ET on October 27, 2021. The management team, including Chairman and CEO Kirk Huntsman and CFO Brad Amman, will discuss innovative treatments for mild to moderate obstructive sleep apnea (OSA) and snoring in adults. The conference runs from October 27-28, 2021. Interested investors can register for a free pass online. Vivos specializes in non-surgical treatments and has successfully treated over 19,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the 3rd-annual Breathing Wellness Conference, set for October 20-23, 2021, in Las Vegas. The event aims to educate dentists and doctors about innovative treatments for patients suffering from obstructive sleep apnea (OSA) and snoring. Key speakers will discuss the implications of OSA on chronic health issues like heart disease and the latest advancements in dentofacial sleep medicine. Vivos strives to provide non-invasive solutions, differentiating itself from traditional treatments like CPAP machines.
Vivos Therapeutics (NASDAQ: VVOS) has announced a strategic collaboration with Candid Care Co. to create a comprehensive solution for diagnosing and treating obstructive sleep apnea (OSA) and providing orthodontic treatment. The partnership aims to integrate Candid's CandidPro aligner system with Vivos' innovative Vivos System. This alliance will focus on shared marketing efforts, educational resources, and specialized training to enhance patient outcomes. Both companies expect to increase market penetration and drive revenue growth through this collaboration, tapping into existing dental and healthcare networks in the U.S. and Canada.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What does Vivos Therapeutics, Inc. specialize in?
What is the Vivos System?
Who can benefit from Vivos Therapeutics' solutions?
How does Vivos Therapeutics collaborate with healthcare providers?
What are some recent achievements of Vivos Therapeutics?
What opportunities have arisen from the recall of CPAP devices?
How does Vivos Therapeutics manufacture its oral appliances?
What makes the Vivos System unique?
Who are the target customers for Vivos Therapeutics?
What is the mission of Vivos Therapeutics?
